Changes in Microbial Ecology After Fecal Microbiota Transplantation for Recurrent C. Difficile Infection Affected by Underlying Inflammatory Bowel Disease

Overview

Journal Microbiome

Publisher Biomed Central

Specialties Genetics
Microbiology

Date 2017 May 17

PMID 28506317

Citations 76

Authors

Sahil Khanna

Yoshiki Vazquez-Baeza

Antonio Gonzalez

Sophie Weiss

Bradley Schmidt

David A Muniz-Pedrogo

John F Rainey 3rd

Patricia Kammer

Heidi Nelson

Michael Sadowsky

Alexander Khoruts

Stefan L Farrugia

Rob Knight

Darrell S Pardi

Purna C Kashyap

Affiliations

Soon will be listed here.

Abstract

Background: Gut microbiota play a key role in maintaining homeostasis in the human gut. Alterations in the gut microbial ecosystem predispose to Clostridium difficile infection (CDI) and gut inflammatory disorders such as inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) from a healthy donor can restore gut microbial diversity and pathogen colonization resistance; consequently, it is now being investigated for its ability to improve inflammatory gut conditions such as IBD. In this study, we investigated changes in gut microbiota following FMT in 38 patients with CDI with or without underlying IBD.

Results: There was a significant change in gut microbial composition towards the donor microbiota and an overall increase in microbial diversity consistent with previous studies after FMT. FMT was successful in treating CDI using a diverse set of donors, and varying degrees of donor stool engraftment suggesting that donor type and degree of engraftment are not drivers of a successful FMT treatment of CDI. However, patients with underlying IBD experienced an increased number of CDI relapses (during a 24-month follow-up) and a decreased growth of new taxa, as compared to the subjects without IBD. Moreover, the need for IBD therapy did not change following FMT. These results underscore the importance of the existing gut microbial landscape as a decisive factor to successfully treat CDI and potentially for improvement of the underlying pathophysiology in IBD.

Conclusions: FMT leads to a significant change in microbial diversity in patients with recurrent CDI and complete resolution of symptoms. Stool donor type (related or unrelated) and degree of engraftment are not the key for successful treatment of CDI by FMT. However, CDI patients with IBD have higher proportion of the original community after FMT and lack of improvement of their IBD symptoms and increased episodes of CDI on long-term follow-up.

Citing Articles

The role of fecal microbiota transplantation in type 2 diabetes mellitus treatment.

Wang H, Li S, Zhang L, Zhang N Front Endocrinol (Lausanne). 2024; 15:1469165.

PMID: 39735647 PMC: 11671274. DOI: 10.3389/fendo.2024.1469165.

PEGylated bacteria restore intestinal mucosal barrier.

Zu M, Xia X, Xiao B Acta Pharm Sin B. 2024; 14(9):4186-4188.

PMID: 39309500 PMC: 11413659. DOI: 10.1016/j.apsb.2024.06.016.

and Gut Microbiota: From Colonization to Infection and Treatment.

Spigaglia P Pathogens. 2024; 13(8).

PMID: 39204246 PMC: 11357127. DOI: 10.3390/pathogens13080646.

A comparative analysis of mutual information methods for pairwise relationship detection in metagenomic data.

Francis D, Sun F BMC Bioinformatics. 2024; 25(1):266.

PMID: 39143554 PMC: 11323399. DOI: 10.1186/s12859-024-05883-7.

Therapeutic Prospects of Mesenchymal Stem Cell and Their Derived Exosomes in the Regulation of the Gut Microbiota in Inflammatory Bowel Disease.

Qiao Y, Tang X, Liu Z, Ocansey D, Zhou M, Shang A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794176 PMC: 11124012. DOI: 10.3390/ph17050607.

References

Faith D, Baker A . Phylogenetic diversity (PD) and biodiversity conservation: some bioinformatics challenges. Evol Bioinform Online. 2009; 2:121-8. PMC: 2674678. View

Khanna S, Tosh P . A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014; 89(1):107-14. DOI: 10.1016/j.mayocp.2013.10.011. View

Kopylova E, Noe L, Touzet H . SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012; 28(24):3211-7. DOI: 10.1093/bioinformatics/bts611. View

Vazquez-Baeza Y, Pirrung M, Gonzalez A, Knight R . EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience. 2013; 2(1):16. PMC: 4076506. DOI: 10.1186/2047-217X-2-16. View

Halfvarson J, Brislawn C, Lamendella R, Vazquez-Baeza Y, Walters W, Bramer L . Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017; 2:17004. PMC: 5319707. DOI: 10.1038/nmicrobiol.2017.4. View

Khanna S, Pardi D . Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. Expert Rev Gastroenterol Hepatol. 2016; 10(10):1145-1152. DOI: 10.1586/17474124.2016.1158097. View

Weingarden A, Gonzalez A, Vazquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D . Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3:10. PMC: 4378022. DOI: 10.1186/s40168-015-0070-0. View

Moayyedi P, Surette M, Kim P, Libertucci J, Wolfe M, Onischi C . Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015; 149(1):102-109.e6. DOI: 10.1053/j.gastro.2015.04.001. View

Lessa F, Winston L, McDonald L . Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372(24):2369-70. PMC: 10880113. DOI: 10.1056/NEJMc1505190. View

10.

Paramsothy S, Kamm M, Kaakoush N, Walsh A, van den Bogaerde J, Samuel D . Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017; 389(10075):1218-1228. DOI: 10.1016/S0140-6736(17)30182-4. View

11.

Knights D, Kuczynski J, Charlson E, Zaneveld J, Mozer M, Collman R . Bayesian community-wide culture-independent microbial source tracking. Nat Methods. 2011; 8(9):761-3. PMC: 3791591. DOI: 10.1038/nmeth.1650. View

12.

Kelly C, Khoruts A, Staley C, Sadowsky M, Abd M, Alani M . Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. Ann Intern Med. 2016; 165(9):609-616. PMC: 5909820. DOI: 10.7326/M16-0271. View

13.

Caporaso J, Kuczynski J, Stombaugh J, Bittinger K, Bushman F, Costello E . QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010; 7(5):335-6. PMC: 3156573. DOI: 10.1038/nmeth.f.303. View

14.

Mandal S, Van Treuren W, White R, Eggesbo M, Knight R, Peddada S . Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015; 26:27663. PMC: 4450248. DOI: 10.3402/mehd.v26.27663. View

15.

Tariq R, Weatherly R, Kammer P, Pardi D, Khanna S . Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. J Clin Gastroenterol. 2016; 52(2):146-150. DOI: 10.1097/MCG.0000000000000768. View

16.

Lozupone C, Knight R . UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005; 71(12):8228-35. PMC: 1317376. DOI: 10.1128/AEM.71.12.8228-8235.2005. View

17.

Staley C, Kelly C, Brandt L, Khoruts A, Sadowsky M . Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation. mBio. 2016; 7(6). PMC: 5181777. DOI: 10.1128/mBio.01965-16. View

18.

Kelly C, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A . Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015; 149(1):223-37. PMC: 4755303. DOI: 10.1053/j.gastro.2015.05.008. View

19.

Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi D . Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2015; 62(5):596-602. DOI: 10.1093/cid/civ938. View

20.

Gevers D, Kugathasan S, Denson L, Vazquez-Baeza Y, Van Treuren W, Ren B . The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15(3):382-392. PMC: 4059512. DOI: 10.1016/j.chom.2014.02.005. View